Choice Institutional Equities's report on Supriya Lifescience
We visited SUPRIYA’s Block E at its Lote facility (in Ratnagiri, Maharashtra) and also met the senior members of the management - Dr. Saloni Wagh (MD) and Mr. Krishna Raghunathan (CFO). Block E houses large-volume, multipurpose synthesis equipment and supports complex/controlled-substance handling. The unit is compliant with global cGMP standards and has significant liquid-filling capabilities. Management highlighted strong progress in backward integration (including KSM development), semi-automated processes that enhance data integrity and readiness for customer and FDA audits. We believe growth will be driven by new launches (3–4 in H2FY26) and CMO opportunities. Ambernath R&D ramp-up will strengthen the portfolio, while improved additional land acquisition and capacity expansion position the company for sustained 20%+ growth. Additionally, the shift towards high margin CDMO and GLP-1 intermediates will also drive margin expansion.
Outlook
We continue to expect to see a CAGR of 21.6%/18.9%/19.4% over FY25-28E and maintain our BUY rating with an unchanged TP of INR 1,030.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
